Chronic fatigue syndrome, formally known as myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS), is not currently classified as an autoimmune disease. The World Health Organization has classified it as a neurological condition since 1969, and it sits under that category in the international disease coding system. However, a growing body of evidence shows the immune system is deeply involved, and some researchers believe ME/CFS may turn out to be autoimmune in at least a subset of patients.
The short answer is that ME/CFS sits in a gray zone. It shares many hallmarks of autoimmune disease, including a female-skewed population, post-infectious onset, and the presence of self-attacking antibodies. But the evidence isn’t consistent enough across all patients to reclassify it, and a major clinical trial testing an autoimmune treatment failed to show clear benefit for the group as a whole.
Why the Autoimmune Question Keeps Coming Up
Several features of ME/CFS mirror classic autoimmune conditions. Roughly four out of five patients are female, a ratio strikingly similar to lupus and Sjögren’s syndrome, which also affect women about four times more often than men. The illness frequently begins after a viral infection, particularly Epstein-Barr virus (EBV), which is a known trigger for multiple autoimmune diseases. And 84% of patients at one specialty clinic had at least one other comorbid condition, with many of those being immune-related problems like Hashimoto’s thyroiditis, mast cell activation disorder, fibromyalgia, and irritable bowel syndrome.
These overlaps aren’t proof, but they create a pattern that’s hard to ignore.
Autoantibodies Found in ME/CFS Patients
The most direct evidence for autoimmunity comes from studies finding elevated levels of autoantibodies in people with ME/CFS. Autoantibodies are immune proteins that mistakenly target the body’s own tissues instead of foreign invaders.
Researchers have found that ME/CFS patients carry higher-than-normal levels of antibodies that bind to two types of receptors involved in the autonomic nervous system: adrenergic receptors, which regulate your fight-or-flight response, energy metabolism, heart function, and immune activation, and muscarinic receptors, which handle nerve-to-muscle communication and brain functions like memory and concentration. When autoantibodies latch onto these receptors, they can disrupt the signals that control heart rate, digestion, blood pressure upon standing, bladder function, and cognitive processing. That disruption maps remarkably well onto the actual symptoms ME/CFS patients experience: orthostatic intolerance, brain fog, muscle weakness, and gastrointestinal problems.
A validation study using blood and spinal fluid from two separate groups of Swedish patients confirmed significant increases in antibodies targeting muscarinic receptors in both groups, with one group also showing elevated antibodies against adrenergic receptors.
How Viral Infections May Spark the Process
Epstein-Barr virus is a leading suspect for triggering autoimmune-like responses in ME/CFS. When EBV first infects someone, it causes a massive, widespread activation of B cells, the immune cells responsible for producing antibodies. This creates a flood of antibodies with many different targets, including some that react against the body’s own tissues. In immunology, this is called polyclonal B cell stimulation.
On top of that, certain EBV proteins look structurally similar to human proteins, a phenomenon called molecular mimicry. The immune system, trained to attack the virus, may continue attacking the body’s own tissues that resemble the viral protein long after the infection clears. EBV also manipulates immune-regulating molecules that normally keep the immune system from turning on itself, further tilting the balance toward autoimmunity.
Immune Cells That Don’t Work Properly
Beyond autoantibodies, ME/CFS patients show broader immune dysfunction. Natural killer cells, which are part of the body’s first line of defense against viruses and abnormal cells, consistently show reduced killing ability in ME/CFS patients compared to healthy people. This impairment is most pronounced in patients with severe illness.
Patients with severe ME/CFS also show elevated levels of inflammatory signaling molecules, including ones that drive inflammation and one that typically tries to suppress it. This simultaneous activation of pro-inflammatory and anti-inflammatory signals suggests the immune system is stuck in a state of confused, chronic activation rather than functioning normally. The natural killer cell problems appear linked to disrupted calcium signaling within the cells, which creates a cascade effect: poor calcium flow leads to weaker cell function, which increases damaging oxidative stress, which further impairs the energy-producing structures inside the cells.
The Energy Production Problem
One of the most tangible findings in ME/CFS research involves mitochondria, the structures inside cells that generate energy. Immune cells from ME/CFS patients produce significantly less energy than those from healthy people. Their cells show lower energy output, reduced ability to generate the molecule that powers cellular work, and impaired baseline energy metabolism.
At the same time, these cells show signs of compensating for the deficit by ramping up backup energy pathways and burning more fat for fuel. This pattern, working harder but producing less, fits with the lived experience of ME/CFS: the body is burning through resources but failing to generate enough usable energy, which helps explain the hallmark symptom of post-exertional malaise, where even minor activity can trigger a crash lasting days.
Whether this mitochondrial dysfunction is caused directly by immune system attack, by the downstream effects of autoantibodies, or by some other mechanism remains an open question.
What a Major Drug Trial Revealed
The strongest test of the autoimmune hypothesis came from clinical trials using rituximab, a drug that destroys B cells (the immune cells that produce antibodies). If ME/CFS were straightforwardly autoimmune, wiping out B cells should help by stopping autoantibody production.
Early, smaller studies showed promising results. But the definitive test, a large, multi-center, placebo-controlled phase III trial called RituxME, found no significant difference between the drug and placebo on any major outcome. Physical function scores improved modestly in both groups over 18 months, and those improvements held at the six-year follow-up regardless of whether patients received the actual drug.
This doesn’t entirely disprove the autoimmune theory, though. The researchers noted that some individual patients did appear to respond to the treatment. One explanation is that ME/CFS isn’t a single disease but a collection of conditions with different underlying mechanisms. In patients whose problematic antibodies are produced by the type of B cell that rituximab targets, the drug may work. In patients whose antibodies come from a different type of immune cell that rituximab can’t reach, it wouldn’t help. There’s currently no reliable way to tell these groups apart before treatment, which makes the drug impractical as a general approach.
How ME/CFS Is Actually Diagnosed
Because there’s no blood test or biomarker that confirms ME/CFS, diagnosis relies on symptom criteria established by the Institute of Medicine in 2015. Three symptoms are required: a substantial drop in your ability to function that lasts more than six months and involves fatigue that is new, not explained by ongoing exertion, and not relieved by rest; post-exertional malaise, where symptoms worsen after physical, mental, or emotional effort that previously wouldn’t have been a problem; and unrefreshing sleep, where a full night’s rest doesn’t reduce tiredness.
You also need at least one of two additional symptoms: cognitive impairment affecting thinking, memory, and information processing, or orthostatic intolerance, where symptoms worsen when you stand up. These symptoms must be present at least half the time at moderate or greater severity.
Where the Science Stands Now
ME/CFS occupies an uncomfortable space in medicine. The immune abnormalities are real and reproducible: autoantibodies, dysfunctional natural killer cells, abnormal inflammatory signaling, and impaired cellular energy production. The demographic and onset patterns parallel autoimmune disease. But the condition doesn’t yet fit neatly into the autoimmune category because the evidence varies between patients, no single autoantibody has been proven to cause the illness, and the largest trial of an autoimmune treatment was negative overall.
The National Institute of Neurological Disorders and Stroke has made ME/CFS a priority, developing a research roadmap presented in 2024 that focuses on the immune system, metabolism, chronic infections, and nervous system involvement. The working hypothesis gaining traction among researchers is that ME/CFS likely involves autoimmune mechanisms in at least some patients, particularly those whose illness began after a viral infection, but that the full picture probably involves multiple interacting systems rather than a single autoimmune process.